Advertorial about apceth Biopharma (in German) published in Transkript 9-2018 Download (pdf)

This phase I/II, first-in-class, first-in-men clinical trial tested safety, tolerability and efficacy of genetically modified mesenchymal stem cells (MSC) in the treatment of advanced, recurrent gastrointestinal cancer. Download publication: Publication_apceth Biopharma_TREAT-ME 1 clinical trial

Geiger S, Hirsch D, Hermann FG. Cell therapy for lung disease Eur Respir Rev. 2017 Jun 28;26(144). Print 2017, Jun 30. Download Publication – Geiger 2017 (PDF)

„Mesenchymal Stromal Cells Protect Endothelial Cells from Cytotoxic T Lymphocyte-Induced Lysis“

apceth, the global innovator and leader

Dr. Christine Günther, apceth CEO, elected as a member of vfa bio Executive Board

apceth joins the race for “The Palo Alto Longevity Prize” under the name “Team Munich”.

apceth experts published a book “Advances in Pharmaceutical Cell Therapy: Principles of Cell-Based Biopharmaceuticals”